NEW YORK (GenomeWeb) – Rubicon Genomics today announced that it has extended a clinical supply agreement providing its TransPlex whole-genome RNA amplification technology to Agendia for use in its MammaPrint 70-Gene breast cancer recurrence assay.

In early 2012, Agendia first inked the deal to use Rubicon's technology to analyze formalin-fixed, paraffin-embedded (FFPE) breast cancer samples on its Symphony suite of diagnostics, which includes MammaPrint.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.